key: cord-0830544-l1d66twp authors: Cheung, Chi Yuen; Chan, Koon Ming; Tang, Gloria; Cheung, Agnes; Chak, Wai Leung title: Immunosuppressive medication adherence in kidney transplant recipients during COVID-19 pandemic: a cross sectional study in Hong Kong date: 2021-08-16 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.08.018 sha: 861ad5a4e887166b55d625572da2b9f7c08f8ad1 doc_id: 830544 cord_uid: l1d66twp BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic has put an enormous burden on healthcare systems worldwide. Limited access to medical care and fear of increased infective risks due to the use of immunosuppressive medication (IM) have increased concerns about IM adherence in kidney transplant recipients (KTR). The aim of this study is to determine the various dimensions of IM non-adherence in KTR during the COVID-19 pandemic. METHODS: This was a single-center, cross-sectional study using a convenient sampling approach. KTR with follow-up in Queen Elizabeth Hospital, Hong Kong between 1st May 2020 and 30th September 2020 were invited to complete a self-reported questionnaire on IM adherence. The sociodemographic factors associated with IM adherence were extracted from medical record. RESULTS: Total 210 patients completed the questionnaires. The overall IM non-adherence rate was 35.2% in the preceding 4 weeks. None of the patients stopped taking IM without doctors’ instructions. The most common pattern of IM non-adherence was timing adherence (n=63, 30.1%), followed by dose-skipping item. Among the different sociodemographic factors studied, only marital status was an independent risk factor of IM non-adherence (OR: 1.97, 95% CI: 1.04-3.72, P=0.03). CONCLUSION: The impact of COVID-19 on IM adherence in KTR was small. All the patients continued their IM despite of the pandemic. Good family support can have a positive influence on treatment adherence in KTR during the COVID-19 pandemic. Kidney transplantation remains the mainstay of treatment for patients suffering from end-stage kidney disease (ESKD). A successful transplantation can offer a better quality of life when compared with those who remain on dialysis treatment (1). However, a major concern in kidney transplantation is patient adherence to immunosuppressive medication (IM) (2, 3) . Many studies have reported that medication non-adherence is a primary reason for graft failure in kidney transplant recipients (KTR) (4, 5) . severe acute respiratory syndrome (SARS) associated coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is putting a huge burden on healthcare systems worldwide. In order to combat the current pandemic, different regions have carried out various measures including lockdowns and mobilization of health care workers to the frontline of the COVID-19 infection. As a result, those patients with chronic diseases requiring regular follow-up may be affected since access to health care facilities and their attending physicians may be denied. Moreover, the worries of being infected in hospitals has discouraged many patients to come back to clinics for follow-up. The limited access to medical care in response to the outbreak are further increasing the concerns about medication adherence in KTR. In addition, it still remains unclear how to best manage IM in transplant recipients during COVID-19. Some patients might simply discontinue the IM due to the fear of increased risks of infection and mortality related to COVID-19 (6, 7) . Hence, a better understanding of the IM adherence in KTR during the pandemic is essential. Non-adherence is often difficult to detect in clinical settings. Although clinical interviews, medical records and drug levels have been used to measure drug adherence, the accuracy of these measures is not certain. Adherence ratings can also vary among different healthcare professionals. In addition, drug level measurements are influenced by various pharmacokinetic factors and can only reflect recent drug consumption (8) . Although electronic monitoring remains the most sensitive and valid measurement method of non-adherence, self-report questionnaires have been recommended as cost-effective and convenient. Self-reported non-adherence is found to be significantly correlated with non-adherence assessed by electronic monitoring, which is viewed as the reference standard (9, 10) . Although the importance of IM adherence in KTR is well documented in literature, the IM adherence in these patients during the COVID-19 pandemic remains unknown. Therefore, we conduct the first study to determine the various dimensions of IM non-adherence in KTR during the COVID-19 pandemic and whether there are any sociodemographic factors that have influenced their behavior. This was a single-center, cross-sectional study using a convenient sampling approach. On 11 th March 2020, World Health Organization declared COVID-19 as a pandemic. The study was conducted in KTR during their routine follow-up visits at the outpatient clinic of Queen Elizabeth Hospital within the period between 1 st May 2020 and 30 th September 2020. Queen Elizabeth Hospital is one of the four major kidney transplant centers in Hong Kong SAR and 402 KTR were cared by our center within the study period. During the pandemic, approximately 20 percent of our patients did not attend the scheduled follow-up appointments in order to avoid SARS-CoV-2 infection. However, all of them had phone contacts with our nurses and then came back to "refill" their medications. The inclusion criteria included: (1) age >=18 years, (2) at least 6 months after transplant, (3) with functioning kidney graft and (4) able to communicate with Chinese language. Most of the patients in our center were on triple immunosuppressive medication including a calcineurin inhibitor (cyclosporine or tacrolimus), mycophenolate or azathioprine and prednisolone. Patients on alternate regimen including a mammalian target of rapamycin inhibitor (sirolimus or everolimus) were also included in our study. The study was approved by the Kowloon Central Cluster Research Ethics Committee (Ref: KC/KE-19-0270/ER4) and was carried out according to the Declaration of Helsinki. In the outpatient clinic, a well-trained renal nurse asked the eligible patients if they would like to participate in a study on IM adherence. Those who signed a consent form would be given a self-reported questionnaire to complete. The Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) was used to assess IM adherence in our study. The BAASIS was developed by the Leuven-Basel Research Ground and has been widely used to measure IM adherence among kidney, heart, liver and lung transplant recipients with established reliability and validity (11, 12) . Permission to use the BAASIS has been granted by the University of Basel. The BAASIS was originally developed in English and has been translated into different languages (including simplified Chinese) before. In this study, the BAASIS was translated into traditional Chinese for KTR in Hong Kong. The questionnaire includes 4 questions which determine the implementation dimension (dose-taking, drug-holiday, timing adherence and dose-alteration) and 1 on discontinuation dimension (stopped-medication) of IM adherence in the preceding 4 weeks. Overall non-adherence was defined as any positive response ("yes") to the 5 questions. The sociodemographic and clinical parameters of the patients including age, gender, educational level, marital status and post-transplant duration were all extracted from the patients' medical record. The statistical analyses were performed by SPSS version 24.0 (IBM Corp, New York, USA). Categorical data were expressed as percentages and were compared with chi-square or Fisher's exact tests while continuous data were expressed as mean +/-standard deviation (SD) and were compared with t-test. Relationship between sociodemographic data and IM adherence were analyzed with multivariate logistic regression analysis. All tests were 2-tailed, and differences for P values of 0.05 or less were considered significant. Total 220 patients consented and participated in this study. Ten patients were excluded from the analysis because of incomplete questionnaires. Of the 210 patients who competed the BAASIS, 57.6% were male and the mean age was 56.0 +/- weeks" was the most commonly cited one (n=63, 30.1%), followed by dose-skipping item ( Table 2 ). Considering the different sociodemographic characteristics studied, only marital status was found to have a statistically significant association with non-adherence (P=0.03) ( Table 1) . Patients who were married had a better IM adherence than patients who remained single/divorced/widowed. When all these sociodemographic factors were entered into the multivariate logistic regression analysis, only marital status was an independent risk factor of IM non-adherence (OR: 1.97, 95% CI: 1.04-3.72, P=0.03). At the time of writing, there was only limited data concerning the impact of COVID-19 on the IM adherence in patients with chronic diseases, but none of them were in KTR. Hence we performed the first study to investigate IM adherence in KTR during COVID-19 pandemic. IM non-adherence can be multifactorial and have been studied extensively in the non-pandemic setting (13) . At the time of COVID-19, shortage of drugs and fear of increased mortality associated with the immunosuppressive effects of medications were common reasons of IM non-adherence in patients with rheumatic diseases (6, 7) . While complete discontinuation of IM was the most common pattern of non-adherence in the rheumatic patients (6), none of the KTR in our study stopped the IM completely without doctors' advice. This is probably because all the patients in our cohort realized the fact that IM discontinuation might lead to acute rejection and graft loss. The prevalence of IM non-adherence in KTR varies widely according to the different measurement tools and evaluation criteria, with empirical evidence reports an average prevalence of 28% (range 8-65%) (14) . In an IM adherence study using BAASIS questionnaire, 55% of KTR were non-adherent with delaying IM doses more common than dose skipping (44% vs 26%) (13) . In another BAASIS study involving Chinese patients, 44.2% of KTR were found to have IM non-adherence, with majority of them being related to timing adherence (41.8% of patients took the IM more than 2 hours before or after recommended dosing times in the past 4 weeks) while only 1.9% of patients stopped the medication completely without doctors' instructions (15) . In our study, overall 35.2% of the respondents were non-adherent to the IM in the past 4 weeks, with all of them having implementation problems. In accordance with other studies (13, 15, 16) , taking non-adherence and dosing non-adherence were low in our cohort. For those patients who reported to have skipped IM doses, 70% of them only missed 1 dose in the previous 4 weeks. The most common pattern of IM non-adherence in our study remained the timing adherence (30.1%). In fact, another study reported that up to 86.7% of KTR could have problems in timing adherence (17) . As forgetfulness is one of the main reasons of medication non-adherence (18) , reducing the number of daily doses such as once daily drug regimen may be able to improve medication adherence (16, 19) . Among the various sociodemographic factors which might affect medication adherence, our study found that KTR who were single, divorced or widowed had a significantly higher risk for IM non-adherence than those who were married. This finding corresponds to a previous study which also showed that marital status was a significant predictor of better IM adherence in KTR (20) . In fact, family support has also been shown to have a positive influence on treatment adherence in patients with chronic diseases (21, 22) . This is particularly important during the COVID-19 pandemic. With concerns about the contagious nature of this virus, patients with chronic diseases are strongly advised to stay at home and avoid unnecessary social contacts even with family members, who often provide support for regular use of therapies. This has left many of them in anxiety and depression as a result of lockdowns and self-isolation (23) . The negative effects of stress on medication adherence have been well documented (24) . There are several limitations in our study. One of the major concerns of self-reported questionnaires is socially desirable answers which may lead to an overestimation of adherence prevalence. In addition, patients who are most likely diagnosed to have IM non-adherence are those who do not attend the clinics as scheduled, therefore are not represented in our cohort. Moreover, other factors related to IM adherence such as self-efficacy, beliefs about medication and therapy-related factors (13) are not explored in this study. Finally, this pandemic may last for a longer time, and with cross-sectional nature of this study, it will be very difficult to study the overall impact of the COVID-19 on the IM non-adherence of KTR for a long period of time. In conclusion, the impact of COVID-19 on IM adherence in KTR was small All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity. The study was approved by the Kowloon Central Cluster Research Ethics Committee Informed consent was obtained from the participants. The cost-effectiveness of increasing kidney transplantation and home-based dialysis Medication noncompliance and its implications in transplant recipients Quantitative patterns of azathioprine adherence after renal transplantation Prevalence and correlates of medication non-adherence among kidney transplant recipients more than 6 months post-transplant: a cross-sectional study Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients The spectrum of nonadherence with medication in heart, liver, and lung transplant patients assessed in various ways The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review Investigating barriers to immunosuppressant medication adherence in renal transplant patients Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review Beliefs of immunosuppressive medication among Chinese renal transplant recipients, as assessed in a cross-sectional study with the Basel Assessment of Adherence to Immunosuppressive Medications Scale Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study Factors associated with adherence to immunosuppressive therapy and barriers in Asian kidney transplant recipients Factors related to immunosuppressant medication adherence in renal transplant recipients Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring Family support, medication adherence, and glycemic control among adults with type 2 diabetes Social participation after kidney transplantation as a predictor of graft loss and mortality over 10 years: a longitudinal study Factors that determine self-reported immunosuppressant adherence in kidney transplant recipients: a correlational study Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 epidemic in China: a web-based cross-sectional survey Mental health in hypertension: assessing symptoms of anxiety, depression and stress on anti-hypertensive medication adherence Nil. All authors have disclosed no conflicts of interest.